Patents by Inventor Audris Huang

Audris Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10633342
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Weifang Shan, Liping Zhang, David K. Williams, Weiwei Guo, Audris Huang, James Aaron Balog
  • Publication number: 20200095231
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 10, 2018
    Publication date: March 26, 2020
    Inventors: James Aaron BALOG, Emily Charlotte CHERNEY, Liping ZHANG, Audris HUANG, Weifang SHAN, David K. WILLIAMS, Xiao ZHU, Weiwei GUO
  • Patent number: 10533014
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 14, 2020
    Assignee: FLEXUS BIOSCIENCES, INC.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • Publication number: 20190282714
    Abstract: The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.
    Type: Application
    Filed: July 18, 2017
    Publication date: September 19, 2019
    Inventors: David J. Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A. Turley, Alban J. Allentoff, Michael Arthur Wallace, James Aaron Balog, Audris Huang, Mette Skinbjerg
  • Patent number: 10399932
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Audris Huang, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • Patent number: 10399933
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Weiwei Guo, Audris Huang, Jay A. Markwalder, Weifang Shan, David K. Williams, Susheel Jethanand Nara, Saumya Roy
  • Publication number: 20190135758
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Inventors: Emily Charlotte CHERNEY, Weifang SHAN, Liping ZHANG, David K. WILLIAMS, Weiwei GUO, Audris HUANG, James Aaron BALOG
  • Patent number: 10206893
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: February 19, 2019
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
  • Publication number: 20190002472
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • Patent number: 10167254
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 1, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • Publication number: 20180325889
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 15, 2018
    Inventors: Hilary Plake BECK, Juan Carlos JAEN, Maksim OSIPOV, Jay Patrick POWERS, Maureen Kay REILLY, Hunter Paul SHUNATONA, James Ross WALKER, Mikhail ZIBINSKY, James Aaron BALOG, David K. Williams, Jay A. MARKWALDER, Steven P. SEITZ, Emily Charlotte CHERNEY, Liping ZHANG, Weifang SHAN, Weiwei GUO, Audris HUANG
  • Patent number: 10106546
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: October 23, 2018
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • Publication number: 20180282281
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: November 5, 2015
    Publication date: October 4, 2018
    Inventors: Hilary Plake BECK, Juan Carios JAEN, Maksim OSIPOV, Jay Patrick POWERS, Maureen Kay REILLY, Hunter Paul SHUNATONA, James Ross WALKER, Mikhail ZIBINSKY, James Aaron BALOG, David K. WILLIAMS, Jay A. MARKWALDER, Emily Charlotte CHERNEY, Welfang SHAN, Audris HUANG
  • Publication number: 20180079712
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 22, 2018
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Audris Huang, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • Publication number: 20180072660
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 15, 2018
    Inventors: James Aaron Balog, Weiwei Guo, Audris Huang, Jay A. Markwalder, Weifang Shan, David K. Williams, Susheel Jethanand Nara, Saumya Roy
  • Patent number: 9895330
    Abstract: There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jay A Markwalder, James Aaron Balog, Audris Huang, Steven P Seitz
  • Patent number: 9790169
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 17, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • Patent number: 9765018
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: September 19, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. Williams, Amy C. Hart, Jennifer Inghrim
  • Patent number: 9758492
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: September 12, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Syngene International Limited
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • Publication number: 20170231999
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla